an anti-self IgE response in a mammal, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.

27. (Amended once) The immunogenic polypeptide of claim 26, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal.

30. (Amended once) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain.

31. (Amended once) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH2 domain.

32. (Amended once) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH4 domain.

33. (Amended once) An immunogenic polypeptide, comprising one or more non-self IgE domains, and an N-terminal half of a self IgE CH3 domain, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.

35. (Amended once) The immunogenic polypeptide of claim 34, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal.

38. (Amended once) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said N-terminal half of a self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain.

39. (Amended once) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain.

40. (Amended once) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH4 domain.

41. (Amended once) An immunogenic polypeptide, comprising a self IgE domain and one or more non-self IgE domains, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, and wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal.

45. (Amended once) The immunogenic polypeptide of claim 41, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain.

46. (Amended once) The immunogenic polypeptide of claim 41, wherein one of said non-self IgE domains is an IgE CH2 domain.

47. (Amended once) The immunogenic polypeptide of claim 41, wherein one of said non-self IgE domains is an IgE CH4 domain.

48. (Amended once) A polypeptide, comprising a self IgE CH3 domain and one or more non-self IgE domains, wherein said polypeptide lacks light chain Ig sequences and is effective to induce an anti-self IgE response in a mammal.

50. (Amended once) The polypeptide of claim 49, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal.